CMPD
MCID: MYL031
MIFTS: 62

Myeloproliferative Neoplasm (CMPD)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloproliferative Neoplasm

MalaCards integrated aliases for Myeloproliferative Neoplasm:

Name: Myeloproliferative Neoplasm 12 55 6 15 38
Chronic Myeloproliferative Disease 12 55
Chronic Myeloproliferative Disorders 53
Chronic Myeloproliferative Disorder 73
Myeloproliferative Disease 73
Campomelic Dysplasia 73
Cmpd, U 12
Cmpd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2226
ICD10 33 D47.1
NCIt 50 C4345
SNOMED-CT 68 20921005

Summaries for Myeloproliferative Neoplasm

NIH Rare Diseases : 53 Chronic myeloproliferative disorders are a group of slow-growing blood cancers in which the bone marrow makes too many abnormal red blood cells, white blood cells, or platelets, which accumulate in the blood. The type of myeloproliferative disorder is based on whether too many red blood cells, white blood cells, or platelets are being made. Sometimes the body will make too many of more than one type of blood cell, but usually one type of blood cell is affected more than the others. There are 6 types of chronic myeloproliferative disorders: chronic myelogenous leukemia (CML), polycythemia vera, primary myelofibrosis (also called chronic idiopathic myelofibrosis), essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. Chronic myeloproliferative disorders sometimes become acute leukemia, in which too many abnormal white blood cells are made.

MalaCards based summary : Myeloproliferative Neoplasm, also known as chronic myeloproliferative disease, is related to myelodysplastic myeloproliferative cancer and atypical chronic myeloid leukemia, and has symptoms including respiratory distress and apnea. An important gene associated with Myeloproliferative Neoplasm is MPL (MPL Proto-Oncogene, Thrombopoietin Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Dasatinib and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A myeloid neoplasm that is characterized by a group of slow growing blood cancers in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.

Wikipedia : 76 The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of... more...

Related Diseases for Myeloproliferative Neoplasm

Diseases related to Myeloproliferative Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 158)
# Related Disease Score Top Affiliating Genes
1 myelodysplastic myeloproliferative cancer 32.9 ABL1 JAK2 PTPN11 TET2
2 atypical chronic myeloid leukemia 32.2 ABL1 JAK2 PDGFRA PDGFRB
3 myelofibrosis 32.0 CALR JAK2 KIT MPL SH2B3 STAT5B
4 pdgfra-associated chronic eosinophilic leukemia 31.8 FIP1L1 PDGFRA
5 essential thrombocythemia 31.5 ABL1 BCR CALR JAK2 MPL SH2B3
6 polycythemia vera 31.3 ABL1 CALR H19 JAK2 JAK3 KIT
7 juvenile myelomonocytic leukemia 31.1 JAK2 JAK3 PDGFRA PDGFRB PTPN11 TET2
8 leukemia, chronic myeloid 31.0 ABL1 BCR FGFR1 H19 JAK2 KIT
9 thrombocytosis 30.9 JAK2 MPL TET2
10 polycythemia 30.9 CALR JAK2 MPL TET2
11 leukemia 30.4 ABL1 BCR JAK2 KIT MPL PTPN11
12 refractory anemia 30.3 JAK2 MPL TET2
13 budd-chiari syndrome 30.3 CALR FIP1L1 JAK2 PDGFRA
14 myelodysplastic syndrome 30.2 ABL1 JAK2 KIT MPL PDGFRB PTPN11
15 myeloid leukemia 30.2 ABL1 BCR JAK2 KIT PTPN11 TET2
16 chronic myelomonocytic leukemia 30.1 JAK2 KIT PDGFRB PTPN11 TET2
17 mastocytosis 30.0 FIP1L1 KIT PDGFRA PDGFRB TET2
18 endomyocardial fibrosis 29.8 FIP1L1 PDGFRA
19 hypereosinophilic syndrome 29.8 ABL1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
20 chronic leukemia 29.7 BCR JAK2 STAT5B TET2
21 systemic mastocytosis 29.7 FGFR1 FIP1L1 JAK2 KIT PDGFRA PDGFRB
22 leukemia, acute myeloid 29.5 ABL1 BCR JAK2 KIT MPL PTPN11
23 bone marrow cancer 28.5 ABL1 BCR CALR FGFR1 JAK2 JAK3
24 campomelic dysplasia 11.9
25 chromosome 14q32 duplication syndrome, 700-kb 11.4
26 myeloproliferative disorder, chronic, with eosinophilia 11.1
27 myeloproliferative syndrome, transient 11.1
28 chronic neutrophilic leukemia 11.1
29 thrombosis 10.7
30 thrombophilia due to thrombin defect 10.4
31 lymphoma 10.4
32 lymphocytic leukemia 10.4
33 subacute myeloid leukemia 10.3 JAK2 TET2
34 leukemia, chronic lymphocytic 2 10.3
35 leukemia, chronic lymphocytic 10.3
36 lymphoblastic lymphoma 10.3
37 leukemia, b-cell, chronic 10.3
38 pdgfrb-associated chronic eosinophilic leukemia 10.3
39 chromosome 8p11 myeloproliferative syndrome 10.2
40 myeloid/lymphoid neoplasm associated with pdgfrb rearrangement 10.2
41 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.2
42 cellular neurofibroma 10.2 ABL1 PDGFRB
43 thrombocythemia 1 10.2 CALR MPL SH2B3
44 reticular perineurioma 10.2 KIT PDGFRA
45 acute promyelocytic leukemia 10.2
46 splenomegaly 10.2
47 desmoid tumor 10.1 KIT PDGFRA PDGFRB
48 philadelphia-negative chronic myeloid leukemia 10.1 ABL1 BCR
49 heart sarcoma 10.1 KIT PDGFRA PDGFRB
50 gastric leiomyosarcoma 10.1 KIT PDGFRA

Graphical network of the top 20 diseases related to Myeloproliferative Neoplasm:



Diseases related to Myeloproliferative Neoplasm

Symptoms & Phenotypes for Myeloproliferative Neoplasm

UMLS symptoms related to Myeloproliferative Neoplasm:


respiratory distress, apnea

GenomeRNAi Phenotypes related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

26 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 10.48 PDGFRA
2 Decreased viability GR00221-A-1 10.48 ABL1 PDGFRA PDGFRB FGFR1 KIT
3 Decreased viability GR00221-A-2 10.48 ABL1 FGFR1
4 Decreased viability GR00221-A-3 10.48 ABL1 JAK3 PDGFRA PDGFRB
5 Decreased viability GR00221-A-4 10.48 PDGFRA PDGFRB
6 Decreased viability GR00301-A 10.48 KIT
7 Decreased viability GR00342-S-1 10.48 ABL1 PDGFRB
8 Decreased viability GR00342-S-2 10.48 ABL1
9 Decreased viability GR00342-S-3 10.48 ABL1
10 Decreased viability GR00402-S-2 10.48 ABL1 JAK3 PDGFRA PDGFRB FGFR1 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.95 ABL1 BCR
12 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.95 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.95 ABL1 JAK3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.95 JAK3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.95 BCR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.95 BCR STAT3
17 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.95 ABL1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.95 BCR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.95 STAT3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.95 JAK3
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.95 ABL1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.95 KIT
23 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.95 ABL1 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.95 BCR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.95 BCR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.95 KIT
27 Increased shRNA abundance (Z-score > 2) GR00366-A-195 9.95 JAK3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.95 BCR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.95 BCR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.95 BCR
31 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.95 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.95 ABL1 KIT
33 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.95 KIT
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.95 ABL1 JAK3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.95 ABL1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.95 JAK3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.95 ABL1 BCR
38 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.95 ABL1 BCR JAK3 KIT STAT3
39 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.95 KIT
40 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.95 JAK3
41 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.95 KIT
42 Decreased substrate adherent cell growth GR00193-A-1 9.73 KIT
43 Decreased substrate adherent cell growth GR00193-A-2 9.73 ABL1 KIT
44 Decreased substrate adherent cell growth GR00193-A-4 9.73 ABL1 FGFR1 KIT
45 Decreased viability in HMC1.1 cells GR00105-A-0 8.96 JAK3 KIT

MGI Mouse Phenotypes related to Myeloproliferative Neoplasm:

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.45 ABL1 BCR CALR FGFR1 JAK2 JAK3
2 hematopoietic system MP:0005397 10.36 ABL1 BCR FGFR1 JAK2 JAK3 KIT
3 growth/size/body region MP:0005378 10.34 ABL1 BCR CALR FGFR1 JAK2 KIT
4 immune system MP:0005387 10.32 ABL1 BCR FGFR1 JAK2 JAK3 KIT
5 endocrine/exocrine gland MP:0005379 10.28 ABL1 FGFR1 JAK2 JAK3 KIT PDGFRA
6 homeostasis/metabolism MP:0005376 10.27 ABL1 BCR CALR FGFR1 JAK2 KIT
7 embryo MP:0005380 10.25 ABL1 CALR FGFR1 JAK2 KIT MPL
8 mortality/aging MP:0010768 10.25 ABL1 BCR CALR FGFR1 JAK2 JAK3
9 cardiovascular system MP:0005385 10.24 ABL1 CALR FGFR1 KIT PDGFRA PDGFRB
10 digestive/alimentary MP:0005381 10.21 ABL1 BCR FGFR1 JAK3 KIT PDGFRA
11 craniofacial MP:0005382 10.11 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
12 integument MP:0010771 10.06 FGFR1 JAK2 KIT PDGFRA PDGFRB PTPN11
13 liver/biliary system MP:0005370 10.03 ABL1 BCR JAK2 KIT PTPN11 STAT3
14 normal MP:0002873 10 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
15 muscle MP:0005369 9.97 ABL1 CALR FGFR1 KIT PDGFRA PDGFRB
16 neoplasm MP:0002006 9.8 JAK2 KIT PDGFRA PTPN11 STAT3 TET2
17 renal/urinary system MP:0005367 9.76 BCR FGFR1 KIT PDGFRA PDGFRB STAT3
18 reproductive system MP:0005389 9.56 FGFR1 JAK2 KIT PDGFRA PDGFRB PTPN11
19 skeleton MP:0005390 9.23 ABL1 FGFR1 JAK2 KIT PDGFRA PDGFRB

Drugs & Therapeutics for Myeloproliferative Neoplasm

Drugs for Myeloproliferative Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 570)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
2
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-98-1 2478
3
Fludarabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
4
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
5
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 127-07-1 3657
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
7
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
8 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
10 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
14 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 tyrosine Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
20 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
25 interferons Phase 4,Phase 3,Phase 2,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 147-94-4 6253
32
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
33
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
34
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
35
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
36
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
37
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
38
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 50-24-8 5755
39
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 302-25-0
40
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 1,Not Applicable 83-43-2 6741
41
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Phase 1,Not Applicable 2921-57-5
42
Iron Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
43
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
44
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
45
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
46
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
47
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
48
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
49
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
50
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 1606)
# Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
3 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
4 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
5 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
6 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
7 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
8 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
9 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
10 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
11 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
12 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
13 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
14 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
15 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
16 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
17 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
18 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
19 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
20 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
21 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
22 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
23 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
24 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
25 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
26 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
27 Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Not yet recruiting NCT01339988 Phase 4 Busulfan/Cyclophosphamide
28 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
29 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
30 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4 Nilotinib 300 mg.
31 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
32 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4 AMN107
33 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
34 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
35 Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Unknown status NCT01800643 Phase 2, Phase 3
36 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
37 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
38 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3 Imatinib
39 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3 cytarabine;hydroxyurea
40 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
41 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
42 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
43 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3 Nilotinib, Imatinib
44 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3 Stem cell Transplantation
45 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
46 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Completed NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
47 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
48 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
49 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
50 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin

Search NIH Clinical Center for Myeloproliferative Neoplasm

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Myeloproliferative Neoplasm

Anatomical Context for Myeloproliferative Neoplasm

MalaCards organs/tissues related to Myeloproliferative Neoplasm:

41
Myeloid, Bone, Bone Marrow, T Cells, Neutrophil, Liver, Kidney

Publications for Myeloproliferative Neoplasm

Articles related to Myeloproliferative Neoplasm:

(show top 50) (show all 300)
# Title Authors Year
1
Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm. ( 29417354 )
2018
2
JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. ( 29767839 )
2018
3
Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals. ( 29645296 )
2018
4
Rapid development of myeloproliferative neoplasm in mice with <i>Ptpn11</i><sup> <i>D61Y</i> </sup> mutation and haploinsufficient for <i>Dnmt3a</i>. ( 29464054 )
2018
5
False-negative <i>CALR</i> mutation in a suspected myeloproliferative neoplasm: identification, resolution and corrective action. ( 29463578 )
2018
6
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. ( 29459662 )
2018
7
<i>Sipa1</i> deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. ( 29514790 )
2018
8
A case of massive splenomegaly due to chronic myeloproliferative neoplasm. ( 29868160 )
2018
9
An evaluation of global coagulation assays in myeloproliferative neoplasm. ( 29538005 )
2018
10
Protracted Clonal Trajectory of a <i>JAK2</i> V617F-Positive Myeloproliferative Neoplasm Developing during Long-Term Remission from Acute Myeloid Leukemia. ( 29854499 )
2018
11
Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. ( 29465270 )
2018
12
Atypical chronic myeloid leukaemia - aA rare subtype of myelodysplastic/myeloproliferative neoplasm. ( 29692658 )
2018
13
Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy. ( 29516749 )
2018
14
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
15
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. ( 29355841 )
2018
16
An unexpected diagnosis: angiosarcoma with bone marrow involvement mimicking a myeloproliferative neoplasm. ( 30203835 )
2018
17
Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm. ( 27650062 )
2018
18
Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia. ( 30170680 )
2018
19
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors. ( 30553471 )
2018
20
Successful Decitabine Treatment in Unfit, Elderly Patients with Acute Myeloid Leukemia following Chronic Myeloproliferative Neoplasm. ( 30384359 )
2018
21
The risk of tuberculosis in cancer patients is greatest in lymphoma and myelodysplastic syndrome/myeloproliferative neoplasm: a large population-based cohort study. ( 30188229 )
2018
22
Anemia with thrombocytosis in an elderly male: a case of myelodysplastic syndrome-myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis. ( 30370419 )
2018
23
Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome/myeloproliferative neoplasm. ( 29992858 )
2018
24
Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. ( 30213875 )
2018
25
A novel type of +2-base pair frameshift CALR mutation in a patient with myeloproliferative neoplasm. ( 29617043 )
2018
26
Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? ( 30033837 )
2018
27
Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. ( 30206308 )
2018
28
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. ( 30222137 )
2018
29
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. ( 30242087 )
2018
30
The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. ( 30277124 )
2018
31
Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study. ( 30352518 )
2018
32
Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm. ( 30377450 )
2018
33
Sequential B-lymphoid and myeloid blastic transformation of Philadelphia chromosome-negative myeloproliferative neoplasm. ( 30407632 )
2018
34
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report. ( 30431598 )
2018
35
Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. ( 30455416 )
2018
36
Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. ( 30463063 )
2018
37
A case of SF3B1 positive myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. ( 30468430 )
2018
38
Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm. ( 28057939 )
2017
39
<i>SETBP1</i> mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome. ( 29225884 )
2017
40
Molecular Investigation of a Suspected Myeloproliferative Neoplasm in Patients with Basophilia. ( 28571160 )
2017
41
The evaluation of the relevance of thrombin generation and procoagulant activity in thrombotic risk assessment in BCR-ABL-negative myeloproliferative neoplasm patients. ( 28497580 )
2017
42
JAK2 exon 12 mutation-positive myeloproliferative neoplasm associated with recurrent thromboembolism. ( 28401106 )
2017
43
Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish. ( 28626217 )
2017
44
Low-dose methotrexate in myeloproliferative neoplasm models. ( 28550185 )
2017
45
Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. ( 28464892 )
2017
46
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm. ( 28668884 )
2017
47
JAK1 somatic mutation in a myeloproliferative neoplasm. ( 28550193 )
2017
48
Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. ( 27687869 )
2017
49
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. ( 28465517 )
2017
50
Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic veinA thrombosis. ( 29048104 )
2017

Variations for Myeloproliferative Neoplasm

ClinVar genetic disease variations for Myeloproliferative Neoplasm:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh37 Chromosome 1, 43814979: 43814979
2 MPL NM_005373.2(MPL): c.1514G> A (p.Ser505Asn) single nucleotide variant Pathogenic/Likely pathogenic rs121913614 GRCh38 Chromosome 1, 43349308: 43349308
3 MPL NM_005373.2(MPL): c.1513A> T (p.Ser505Cys) single nucleotide variant Likely pathogenic rs1057519752 GRCh37 Chromosome 1, 43814978: 43814978
4 MPL NM_005373.2(MPL): c.1513A> T (p.Ser505Cys) single nucleotide variant Likely pathogenic rs1057519752 GRCh38 Chromosome 1, 43349307: 43349307
5 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh37 Chromosome 19, 17948009: 17948009
6 JAK3 NM_000215.3(JAK3): c.1715C> T (p.Ala572Val) single nucleotide variant Likely pathogenic rs121913504 GRCh38 Chromosome 19, 17837200: 17837200
7 KIT NM_000222.2(KIT): c.1675G> A (p.Val559Ile) single nucleotide variant Likely pathogenic rs121913520 GRCh37 Chromosome 4, 55593609: 55593609
8 KIT NM_000222.2(KIT): c.1675G> A (p.Val559Ile) single nucleotide variant Likely pathogenic rs121913520 GRCh38 Chromosome 4, 54727443: 54727443

Copy number variations for Myeloproliferative Neoplasm from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 33241 1 43803475 43820135 Mutation MPL Myeloproliferative neoplasm
2 44192 10 53300000 71300000 Loss Myeloproliferative neoplasm
3 62279 12 107500000 132349534 Loss Myeloproliferative neoplasm
4 70916 12 66000000 69800000 Loss Myeloproliferative neoplasm
5 71420 12 69800000 91200000 Loss Myeloproliferative neoplasm
6 75262 13 18400000 31100000 Loss Myeloproliferative neoplasm
7 75265 13 18400000 72100000 Loss Myeloproliferative neoplasm
8 92698 15 42700000 55800000 Loss Myeloproliferative neoplasm
9 93011 15 47498995 47525965 Loss FGF7 Myeloproliferative neoplasm
10 106738 17 1 11200000 Loss Myeloproliferative neoplasm
11 108733 17 22200000 28800000 Loss Myeloproliferative neoplasm
12 109394 17 25800000 31800000 Deletion NF1 Myeloproliferative neoplasm
13 114437 17 47600000 54900000 Loss Myeloproliferative neoplasm
14 115165 17 55117687 55118542 Loss CLTC Myeloproliferative neoplasm
15 124069 19 1 19800000 Loss Myeloproliferative neoplasm
16 126326 19 18251575 18251854 Loss JUND Myeloproliferative neoplasm
17 127984 19 38473374 38495178 Loss CEBPA Myeloproliferative neoplasm
18 142294 2 221300000 230700000 Loss Myeloproliferative neoplasm
19 147392 2 64000000 83700000 Loss Myeloproliferative neoplasm
20 150691 20 40134805 41251971 Copy number PTPRT Myeloproliferative neoplasm
21 150692 20 41976905 42131668 Copy number TOX2 Myeloproliferative neoplasm
22 151958 20 27100000 62435964 Loss Myeloproliferative neoplasm
23 151974 20 27500000 63025520 Deletion L3MBTL Myeloproliferative neoplasm
24 158649 21 35044781 35543405 Loss RUNX1 Myeloproliferative neoplasm
25 164350 22 36286416 36295356 Translate CEP1 Myeloproliferative neoplasm
26 164841 22 39916010 39959748 Gain L3MBTL2 Myeloproliferative neoplasm
27 166129 3 1 8700000 Loss Myeloproliferative neoplasm
28 170893 3 161200000 184200000 Loss Myeloproliferative neoplasm
29 177254 3 54400000 71800000 Loss Myeloproliferative neoplasm
30 179193 3 8700000 30800000 Gain Myeloproliferative neoplasm
31 192210 5 108662279 108714138 Gain PJA2 Myeloproliferative neoplasm
32 196632 5 17000000 76400000 Loss Myeloproliferative neoplasm
33 199864 5 44387421 44399741 Loss FGF10 Myeloproliferative neoplasm
34 227798 7 7200000 19500000 Loss Myeloproliferative neoplasm
35 230718 8 1 12700000 Loss Myeloproliferative neoplasm
36 233709 8 12700000 19100000 Loss Myeloproliferative neoplasm
37 241221 8 59800000 106100000 Loss Myeloproliferative neoplasm
38 244938 9 1 49000000 LOH JAK2 Myeloproliferative neoplasm
39 246129 9 116700000 129300000 Loss Myeloproliferative neoplasm

Expression for Myeloproliferative Neoplasm

Search GEO for disease gene expression data for Myeloproliferative Neoplasm.

Pathways for Myeloproliferative Neoplasm

Pathways related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.21 ABL1 BCR FGFR1 JAK2 JAK3 KIT
2
Show member pathways
14.07 ABL1 CALR FGFR1 JAK2 JAK3 KIT
3
Show member pathways
13.89 ABL1 FGFR1 JAK2 JAK3 KIT PDGFRA
4
Show member pathways
13.74 BCR CALR FGFR1 JAK2 KIT PDGFRA
5
Show member pathways
13.72 FGFR1 JAK2 JAK3 KIT MPL PDGFRA
6
Show member pathways
13.54 FGFR1 JAK2 JAK3 KIT MPL PDGFRA
7
Show member pathways
13.52 ABL1 FGFR1 JAK2 JAK3 KIT PDGFRA
8
Show member pathways
13.44 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
9
Show member pathways
13.35 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
10
Show member pathways
13.23 ABL1 JAK2 JAK3 MPL STAT3 STAT5B
11
Show member pathways
13.08 FGFR1 JAK2 KIT PDGFRA PDGFRB STAT3
12
Show member pathways
13.04 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
13
Show member pathways
12.95 JAK2 JAK3 PDGFRA PDGFRB STAT3 STAT5B
14
Show member pathways
12.91 CALR JAK2 JAK3 STAT3 STAT5B
15
Show member pathways
12.9 FGFR1 JAK2 JAK3 PDGFRA PDGFRB STAT3
16
Show member pathways
12.83 JAK2 JAK3 PTPN11 STAT3 STAT5B
17
Show member pathways
12.82 JAK2 JAK3 MPL PTPN11 STAT3 STAT5B
18
Show member pathways
12.77 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
19
Show member pathways
12.76 FGFR1 KIT PDGFRA PDGFRB PTPN11
20
Show member pathways
12.74 FGFR1 JAK2 JAK3 PDGFRA PDGFRB STAT3
21
Show member pathways
12.66 ABL1 BCR FGFR1 KIT PDGFRA PDGFRB
22
Show member pathways
12.63 JAK2 PDGFRA PDGFRB PTPN11 STAT3 STAT5B
23 12.6 JAK2 JAK3 KIT MPL STAT3 STAT5B
24 12.54 ABL1 PDGFRA PDGFRB STAT3
25
Show member pathways
12.51 JAK2 PTPN11 STAT3 STAT5B
26
Show member pathways
12.5 ABL1 PTPN11 STAT3 STAT5B
27 12.47 CALR JAK3 PDGFRA PDGFRB STAT5B
28
Show member pathways
12.44 KIT PDGFRA PDGFRB PTPN11
29
Show member pathways
12.44 JAK2 JAK3 PTPN11 STAT3 STAT5B
30
Show member pathways
12.43 JAK2 JAK3 PTPN11 STAT3
31
Show member pathways
12.43 FGFR1 KIT PDGFRA PDGFRB STAT3
32 12.38 ABL1 BCR FGFR1 JAK2 JAK3 KIT
33
Show member pathways
12.37 JAK2 JAK3 STAT3 STAT5B
34
Show member pathways
12.35 FGFR1 JAK2 JAK3 PTPN11
35
Show member pathways
12.31 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
36
Show member pathways
12.3 JAK2 JAK3 PTPN11 STAT3 STAT5B
37
Show member pathways
12.26 JAK2 JAK3 STAT3 STAT5B
38 12.22 ABL1 JAK2 PTPN11 STAT3 STAT5B
39
Show member pathways
12.21 BCR FGFR1 STAT3 STAT5B
40
Show member pathways
12.18 PDGFRA PDGFRB PTPN11 STAT3
41 12.15 JAK2 PTPN11 STAT3 STAT5B
42 12.13 FGFR1 JAK2 JAK3 STAT3
43
Show member pathways
12.12 JAK2 KIT PTPN11 SH2B3 STAT3 STAT5B
44
Show member pathways
12.1 JAK2 JAK3 STAT3 STAT5B
45
Show member pathways
12.09 JAK2 JAK3 PTPN11 STAT3 STAT5B
46 12.01 KIT MPL SH2B3
47
Show member pathways
12.01 JAK2 JAK3 PTPN11 STAT5B
48 12 JAK2 JAK3 STAT3
49 11.93 JAK2 STAT3 STAT5B
50
Show member pathways
11.91 BCR FGFR1 STAT3 STAT5B

GO Terms for Myeloproliferative Neoplasm

Cellular components related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.77 ABL1 BCR CALR CEP85L FGFR1 JAK2
2 protein-containing complex GO:0032991 9.65 ABL1 BCR CALR PDGFRA PTPN11
3 cell surface GO:0009986 9.55 CALR KIT MPL PDGFRA PDGFRB
4 receptor complex GO:0043235 8.92 FGFR1 KIT PDGFRA PDGFRB

Biological processes related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 ABL1 FGFR1 KIT PDGFRA PDGFRB PTPN11
2 positive regulation of cell migration GO:0030335 9.97 JAK2 KIT PDGFRA PDGFRB STAT3
3 MAPK cascade GO:0000165 9.97 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
4 positive regulation of MAPK cascade GO:0043410 9.96 FGFR1 KIT PDGFRA PDGFRB
5 positive regulation of protein kinase B signaling GO:0051897 9.95 FGFR1 KIT PDGFRA PDGFRB PTPN11
6 cytokine-mediated signaling pathway GO:0019221 9.95 JAK2 JAK3 KIT MPL PTPN11 STAT3
7 negative regulation of signal transduction GO:0009968 9.92 FGFR1 KIT PDGFRA PDGFRB
8 phosphatidylinositol phosphorylation GO:0046854 9.92 FGFR1 KIT PDGFRA PDGFRB PTPN11
9 response to estradiol GO:0032355 9.9 CALR PDGFRB STAT3 STAT5B
10 cell chemotaxis GO:0060326 9.89 KIT PDGFRA PDGFRB
11 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.89 KIT PDGFRA PDGFRB SH2B3
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 JAK2 KIT STAT3
13 modulation of chemical synaptic transmission GO:0050804 9.86 BCR JAK2 STAT3
14 positive regulation of MAP kinase activity GO:0043406 9.86 FGFR1 KIT PDGFRB
15 erythrocyte differentiation GO:0030218 9.85 JAK2 JAK3 KIT
16 phosphatidylinositol-mediated signaling GO:0048015 9.85 FGFR1 PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 FGFR1 JAK2 KIT PDGFRA PDGFRB
18 positive regulation of mitotic cell cycle GO:0045931 9.81 ABL1 PTPN11 STAT5B
19 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.81 KIT PDGFRA PDGFRB
20 interleukin-7-mediated signaling pathway GO:0038111 9.8 JAK3 STAT3 STAT5B
21 regulation of multicellular organism growth GO:0040014 9.79 PTPN11 STAT3 STAT5B
22 JAK-STAT cascade GO:0007259 9.79 JAK2 STAT3 STAT5B
23 interleukin-6-mediated signaling pathway GO:0070102 9.74 JAK2 PTPN11 STAT3
24 regulation of actin cytoskeleton reorganization GO:2000249 9.73 ABL1 PDGFRA
25 embryonic hemopoiesis GO:0035162 9.73 KIT SH2B3
26 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.73 JAK2 PDGFRB
27 interleukin-15-mediated signaling pathway GO:0035723 9.73 JAK3 STAT3 STAT5B
28 megakaryocyte development GO:0035855 9.72 KIT PTPN11
29 negative regulation of cell-cell adhesion GO:0022408 9.72 ABL1 JAK2
30 growth hormone receptor signaling pathway GO:0060396 9.72 JAK2 STAT3
31 interleukin-27-mediated signaling pathway GO:0070106 9.72 JAK2 STAT3
32 interleukin-2-mediated signaling pathway GO:0038110 9.71 JAK3 STAT5B
33 interleukin-35-mediated signaling pathway GO:0070757 9.71 JAK2 STAT3
34 regulation of JAK-STAT cascade GO:0046425 9.71 JAK2 JAK3
35 interleukin-23-mediated signaling pathway GO:0038155 9.71 JAK2 STAT3
36 postsynapse to nucleus signaling pathway GO:0099527 9.71 JAK2 STAT3
37 interleukin-9-mediated signaling pathway GO:0038113 9.71 JAK3 STAT3 STAT5B
38 tyrosine phosphorylation of STAT protein GO:0007260 9.7 JAK2 JAK3
39 Bergmann glial cell differentiation GO:0060020 9.7 ABL1 PTPN11
40 enzyme linked receptor protein signaling pathway GO:0007167 9.7 JAK2 JAK3
41 protein autophosphorylation GO:0046777 9.7 ABL1 BCR FGFR1 JAK2 KIT PDGFRA
42 interleukin-21-mediated signaling pathway GO:0038114 9.69 JAK3 STAT3
43 retina vasculature development in camera-type eye GO:0061298 9.69 PDGFRA PDGFRB
44 luteinization GO:0001553 9.68 PDGFRA STAT5B
45 response to interleukin-4 GO:0070670 9.68 JAK3 STAT5B
46 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.67 ABL1 PDGFRB
47 metanephric glomerular capillary formation GO:0072277 9.66 PDGFRA PDGFRB
48 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.65 PDGFRA PDGFRB
49 response to interleukin-15 GO:0070672 9.65 JAK3 STAT5B
50 response to interleukin-2 GO:0070669 9.65 JAK3 STAT5B

Molecular functions related to Myeloproliferative Neoplasm according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.88 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
2 protein kinase activity GO:0004672 9.87 ABL1 FGFR1 JAK2 JAK3 KIT PDGFRA
3 kinase activity GO:0016301 9.86 ABL1 BCR FGFR1 JAK2 JAK3 KIT
4 transmembrane signaling receptor activity GO:0004888 9.83 FGFR1 KIT MPL PDGFRA PDGFRB
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.67 FGFR1 KIT PDGFRA PDGFRB
6 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.65 ABL1 JAK2 JAK3
7 glucocorticoid receptor binding GO:0035259 9.58 STAT3 STAT5B
8 platelet-derived growth factor receptor binding GO:0005161 9.57 PDGFRA PDGFRB
9 insulin receptor substrate binding GO:0043560 9.56 JAK2 PTPN11
10 platelet-derived growth factor binding GO:0048407 9.55 PDGFRA PDGFRB
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.55 FGFR1 KIT PDGFRA PDGFRB PTPN11
12 peptide hormone receptor binding GO:0051428 9.54 JAK2 PTPN11
13 vascular endothelial growth factor binding GO:0038085 9.49 PDGFRA PDGFRB
14 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 FGFR1 JAK2 JAK3 KIT PDGFRA PDGFRB
15 protein tyrosine kinase activity GO:0004713 9.28 ABL1 BCR FGFR1 JAK2 JAK3 KIT
16 protein binding GO:0005515 10.41 ABL1 BCR CALR FGFR1 FIP1L1 JAK2
17 transferase activity GO:0016740 10.13 ABL1 BCR FGFR1 JAK2 JAK3 KIT
18 ATP binding GO:0005524 10.06 ABL1 BCR FGFR1 JAK2 JAK3 KIT

Sources for Myeloproliferative Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....